Domain-Specific Improvement of Cognition on Memantine in Patients with Alzheimer’s Disease Treated with Rivastigmine
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: Cholinergic therapy is used in mild-to-moderate Alzheimer’s disease (AD) and antiglutamatergic therapy in moderate-to-severe AD. Global scales, as commonly used in clinical trials, blur specifics of disease progression and drug effects. The objective was to assess combination therapy of rivastigmine plus memantine by specific neuropsychological tests in patients with mild-to-moderate AD. Methods: 12-week-short multicenter open-label pilot study. Ninety patients with mild-to-moderate AD already on stable medication with rivastigmine (3–6 mg b.i.d.) additionally received memantine for 12 weeks. Subscales of the Alzheimer’s Disease Assessment Scale (ADAS-cog), the Mini-Mental State Examination (MMSE) and additional neuropsychological tests (e.g. span tasks, semantic fluency) were assessed. Results: The scores in the ADAS-cog memory subscale, the MMSE score, and digit span and semantic fluency significantly improved on combination therapy. Conclusion: Memory improvement was correlated with ADAS-cog memory score at baseline and inversely with age at onset of treatment. The data suggest that improvement on combination therapy results from an improvement of attention/executive function with secondary memory improvement, which will need to be confirmed in a subsequent double-blind study on a larger number of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Control Functions of the Frontal Lobes. Modularity of the Central-Supervisory System?
Godefroy, O., Cabaret, M., Petit-Chenal, V., Pruvo, J.-P., & Rousseaux, M. (1999) · Cortex · doi:10.1016/s0010-9452(08)70782-2 · Cited by 141
Doody, R., Wirth, Y., Schmitt, F., & Möbius, H. J. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079833 · Cited by 52 · cited 1×
“Recently, the combination of memantine and cholinesterase inhibitors has been assessed in moderate-to-severe AD [”
Background
Cited by
Therapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Therapeutics of Neurotransmitters in Alzheimer’s Disease
Kandimalla, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161118 · Cited by 268
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
Carpenter, W. T., Bustillo, J. R., Thaker, G. K., van Os, J., Krueger, R. F., & Green, M. J. (2009) · Psychological Medicine · doi:10.1017/s0033291709990286 · Cited by 99
Metadata
- Authors
- Riepe, M. W., Adler, G., Ibach, B., Weinkauf, B., Tracik, F., & Gunay, I.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 23
- Issue
- 5
- Pages
- 301-306
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2037640718
- Cited by
- 34
- References
- 7
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Domain-Specific Improvement of Cognition on Memantine in Patients with Alzheimer’s Disease Treated with Rivastigmine. https://app.cochat.ai/papers/10.1159/000100875
- The paper
- Riepe, M. W., Adler, G., Ibach, B., Weinkauf, B., Tracik, F., & Gunay, I. (2007). Domain-Specific Improvement of Cognition on Memantine in Patients with Alzheimer’s Disease Treated with Rivastigmine. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000100875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.